ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“Inconsistent definitions of lines of therapy (LoT) contribute to variability in clinical practice and limit the comparability of results across clinical trials, particularly in later-line treatment settings.
A new ESMO consensus-driven document addresses this challenge by providing definitions, formats and minimum required data for the uniform enumeration and reporting of prior lines of therapy across solid tumours.
Through EnLiST (the ESMO Adaptation of Lines of Systemic Therapy), this approach supports more consistent patient selection, clearer interpretation of trial outcomes, and more robust evidence generation across oncology research.”
More posts about ESMO.
